Equities

X T L Biopharmaceuticals Ltd

X T L Biopharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)2.18
  • Today's Change-0.09 / -3.96%
  • Shares traded52.58k
  • 1 Year change+67.68%
  • Beta1.2233
Data delayed at least 15 minutes, as of Jun 10 2024 20:53 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

XTL Biopharmaceuticals Ltd is an Israel-based biopharmaceutical company engaged in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. The Company pipelines include hCDR1 systematic lupus erythematosus and recombinant human erythropoietin (rHuEPO) multiple myeloma. Its hCDR1, which is a potential treatment for systemic lupus erythematosus (SLE) and Sjogren's syndrome (SS). hCDR1 is a peptide that is administered subcutaneously and acts as a disease-specific treatment to modify the SLE-related autoimmune process. The rHuEPO known agent for anemia to prolong the survival of patients for the treatment of multiple myeloma blood cancer. Its Erythropoietin (EPO) is a glycoprotein hormone produced mainly by the kidney. EPO stimulates erythropoiesis, the production of red blood cells, by binding to its receptor on the surface of erythroid progenitor cells, promoting their proliferation and differentiation and maintaining their viability.

  • Revenue in USD (TTM)0.00
  • Net income in USD-1.78m
  • Incorporated1993
  • Employees0.00
  • Location
    X T L Biopharmaceuticals Ltd5 Badner St.,P.O.Box 8241RAMAT GAN 5218102IsraelISR
  • Phone+972 99557080
  • Fax+972 99519708
  • Websitehttps://www.xtlbio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Marizyme Inc549.70k-69.02m12.26m11.00------22.30-1.42-1.420.0081-0.08220.01841.6514.0649,972.73-230.68-59.02-531.63-64.4771.1770.38-12,555.69-9,435.920.0279-0.58371.92--176.5999.98-71.22------
Energy Finders Inc4.06m-2.92m12.30m46.00------3.03-0.272-0.2721.523.04------88,304.35--------27.45---71.79--0.6706-12.570.564--------------
Kiora Pharmaceuticals Inc16.00m2.28m12.34m12.00--0.35365.310.7713-1.60-1.601.211.330.5427--8.641,333,333.009.52-70.5210.17-81.86----17.55-2,040.61----0.00------3.97------
Dominari Holdings Inc3.41m-24.56m12.37m26.00--0.2594--3.63-4.64-4.640.63058.030.0539--0.8023131,000.00-38.88-26.82-39.93-27.45-----721.11-3,353.52----0.00----135.7512.72--63.99--
Guardion Health Sciences Inc12.06m-5.12m12.71m9.00--3.72--1.05-4.00-4.009.492.660.97182.635.961,340,280.00-41.26-77.90-47.92-86.5543.4342.45-42.46-176.936.49-4.240.00--10.8567.03101.00---58.56--
Senti Biosciences Inc1.28m-86.11m12.84m48.00--0.2287--10.07-1.93-1.440.02851.230.0097--2.9426,562.50-65.33---71.42-------6,753.80------0.0018---40.25---67.94------
Check Cap Ltd0.00-17.57m12.99m85.00--0.5484-----3.00-3.000.004.050.00-------49.87-54.23-53.46-60.24------------0.00------8.06---2.46--
X T L Biopharmaceuticals Ltd (ADR)0.00-1.78m13.05m0.00--5.57-----0.327-0.3270.000.40740.00-------53.90-21.36-57.31-22.20------------0.00-------32.20------
Cell MedX Corp70.00-96.91k13.08m0.00------186,834.30-0.0029-0.00290.00-0.00240.0015-------202.28-792.55-----685.71---138,442.90-3,681.84---3.17-----54.53--29.01------
Nexgel Inc4.74m-3.20m13.20m19.00--2.76--2.79-0.5535-0.55350.82080.76880.44283.248.46249,263.20-30.72-44.61-39.92-56.1920.145.02-69.38-180.981.41--0.1819--99.6613.0633.48------
Plus Therapeutics Inc (USA)6.08m-11.77m13.40m20.00------2.20-3.19-3.191.67-1.130.5724----304,200.00-110.75-59.18---133.04-----193.49-470.45--------2,093.30-5.8934.32--3.77--
Pieris Pharmaceuticals Inc40.93m-16.25m13.53m46.00--0.5771--0.3307-12.74-12.7434.0517.760.7324--28.25889,717.40-29.09-28.41-52.98-39.69-----39.71-94.61----0.00--65.288.0326.25---36.82--
Nascent Biotech Inc0.00-2.09m13.56m----443.91-----0.0147-0.01470.000.00020.00-------346.80-815.53-----------548.75----0.8045---100.00---495.46------
Organovo Holdings Inc109.00k-14.67m13.80m12.00--2.69--126.60-1.62-1.620.01190.35730.0082--1.185,450.00-110.05-54.25-138.86-58.42-----13,459.63-1,890.161.96--0.00---70.54-48.7815.00---11.87--
Data as of Jun 10 2024. Currency figures normalised to X T L Biopharmaceuticals Ltd's reporting currency: US Dollar USD

Institutional shareholders

4.75%Per cent of shares held by top holders
HolderShares% Held
Noked Capital Ltd.as of 31 Mar 2024198.89k3.65%
Morgan Stanley & Co. LLCas of 31 Mar 202439.17k0.72%
Citadel Securities LLCas of 31 Mar 202413.63k0.25%
UBS Securities LLCas of 31 Mar 20246.95k0.13%
BNP Paribas Financial Marketsas of 31 Mar 2024300.000.01%
Central Trust Co. (Missouri)as of 31 Mar 20240.000.00%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.